Why AI Needs Physics to Grow Up

by Ashutosh Jogalekar

There has long been a temptation in science to imagine one system that can explain everything. For a while, that dream belonged to physics, whose practitioners, armed with a handful of equations, could describe the orbits of planets and the spin of electrons. In recent years, the torch has been seized by artificial intelligence. With enough data, we are told, the machine will learn the world. If this sounds like a passing of the crown, it has also become, in a curious way, a rivalry. Like the cinematic conflict between vampires and werewolves in the Underworld franchise, AI and physics have been cast as two immortal powers fighting for dominion over knowledge. AI enthusiasts claim that the laws of nature will simply fall out of sufficiently large data sets. Physicists counter that data without principle is merely glorified curve-fitting.

A recent experiment brought this tension into sharp relief. Researchers trained an AI model on the motions of the planets and found that it could predict their positions with exquisite precision. Yet when they looked inside the model, it had discovered no sign of Newton’s law of gravitation — no trace of the famous inverse-square relation that binds the solar system together. The machine had mastered the music of the spheres but not the score. It had memorized the universe, not understood it.

This distinction between reproducing a pattern and understanding its cause may sound philosophical, but it has real consequences. Nowhere is that clearer than in the difficult art of discovering new drugs.

Every effective drug is, at heart, a tiny piece of molecular architecture. Most are small organic molecules that perform their work by binding to a protein in the body, often one that is overactive or misshapen in disease. The drug’s role is to fit into a cavity in that protein, like a key slipping into a lock, and alter its function.

Finding such a key, however, is far from easy. A drug must not only fit snugly in its target but must also reach it, survive long enough to act, and leave the body without causing harm. These competing demands make drug discovery one of the most intricate intellectual endeavors humans have attempted. For centuries, we relied on accident and observation. Willow bark yielded aspirin; cinchona bark gave us quinine. Then, as chemistry, molecular biology, and computing matured in the latter half of the twentieth century, the process became more deliberate. Once we could see the structure of a protein – thanks to x-ray crystallography – we could begin to design molecules that might bind to it. Read more »

Wednesday, February 19, 2025

An ingenious new treatment for schizophrenia

by Ashutosh Jogalekar

Molecular structures of xanomeline and trospium chloride. Note the positive charge (indicated by a +) on trospium chloride that restricts its actions to outside the brain.

Drugs for mental illness are notoriously hard. Human biology is complex, and the brain is even more complicated. We now have a good understanding of the basic mechanisms of neurotransmission, but the drugs we have for treating disorders like depression, anxiety and psychosis are often “spray and pray” approaches, either targeting the wrong mechanisms of dysfunction or targeting too many or too few. Antidepressants often stop working. Anti-anxiety medication can do little more than sedate. And many antipsychotic drugs have prohibitive side effects.

Nevertheless, there are rare cases when genuine breakthroughs occur in the field. Thorazine famously emptied out the cruel mental asylums of the 1950s and 1960s. L-DOPA provided genuine benefits for Parkinson’s patients. And there is no denying that the new generation of antidepressants works at least occasionally for a subset of patients. Last year one such potential breakthrough seemed to fly under the radar of breathless news dominated by politics and social issues. If its promise holds up, it could herald a new kind of treatment for schizophrenia.

As is well known, schizophrenia is a serious form of psychosis that is characterized by disordered thinking, hallucinations and impaired speech and expression. The disease profoundly impacts the quality of life of afflicted individuals, including being able to sustain social relationships and professional goals. In severe cases, as made infamous by the case of Michael Laudor, even high-functioning schizophrenics can become a fatal threat to themselves or others. Estimates of the prevalence of schizophrenia in the United States range from 0.25%-0.64%.

All drugs work by blocking or improving the function of proteins or receptors. Receptors in the brain include those that regulate the function of neurotransmitters like dopamine, serotonin and norepinephrine. Neuropharmacological drug discovery starts with identifying these receptors and then discovering molecules that selectively inhibit or activate them. For instance, most antidepressants are selective serotonin reuptake inhibitors (SSRIs) which increase the concentration of serotonin by blocking its re-absorbption and improving a sense of well-being. Read more »